Median eyonis
-
FDA Clears eyonis® LCS Software for U.S. Lung Cancer Screening Market; Oran Muduroglu Named President of Median eyonis Inc.
The FDA has cleared eyonis® LCS, an AI-powered software for lung cancer screening. This approval allows for its U.S. commercialization, enabling earlier and more accurate detection of lung nodules by analyzing medical images. This advancement, driven by sophisticated AI in healthcare, could significantly improve patient outcomes and survival rates for lung cancer. The company also appointed Oran Muduroglu as President to guide its market growth and development.